Trial · NCT03817749
Ketone Supplementation, Glucose Control, and Cardiovascular Function
NCT03817749, Not applicable, Completed, University of British Columbia
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Ketone Supplementation, Glucose Control, and Cardiovascular Function. Trials, record NCT03817749. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03817749
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Ketone Supplementation, Glucose Control, and Cardiovascular Function
- NCT number
- NCT03817749
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 15 participants, actual
- Lead sponsor
- University of British Columbia
- Conditions
- Hyperglycemia, Postprandial, Overweight and Obesity, Diabetes Mellitus Risk
- Interventions
- Exogenous ketone monoester
- First posted
- 2019-01-25
- Last updated
- 2021-04-28
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Glucose control | 2 hours after a meal | Post-prandial glucose excursions will be measured by continuous glucose monitoring using the iPro2 CGM by Medtronic in both the active and placebo supplement conditions. Post-prandial glucose following breakfast, lunch, and dinner will be averaged together. |
| Secondary | Change from baseline flow mediated dilation at 14 days | Day 0 (Pre-intervention) and Day 14 (post-intervention) | Vascular function will be assessed by flow mediated dilation of the brachial artery using vascular ultrasound. A cuff will affixed on the forearm, distal to the brachial artery and will be inflated for 5 minutes. Flow mediation dilation will be measured over a 3-minute period following cuff release. |
| Secondary | Change from baseline histone acetylation at 14 days | Day 0 (Pre-intervention) and Day 14 (post-intervention) | Histone H3 acetylation status will be quantified by flow cytometry using conjugated acetyl-histone H3 antibody specific for Lys9 (Pacific Blue 445) and the conjugated acetyl-histone H3 antibody specific for Lys14 (Alexa Fluor 488). |
| Secondary | Change from baseline mitochondrial superoxide production at 14 days | Day 0 (Pre-intervention) and Day 14 (post-intervention) | Oxidative Stress will be measured by mitochondrial superoxide production in blood lymphocytes, monocytes, and neutrophils by flow cytometry using the MitoSOX red assay (ThermoFisher #M36008) and total intracellular ROS via the DCFDA assay (Sigma #D6883) |
| Secondary | Change from baseline cognition (executive functions) at 14 days | Day 0 (Pre-intervention) and Day 14 (post-intervention) | Cognition will be assessed using a customized battery of psychometrically validated tests within the domain of executive functions using the iPad-based app BrainBaseline. The tests will be the Stroop test, task-switching test, digit-symbol substitution test, and the n-back test. |
| Secondary | Change from baseline plasma glucose at 14 days | Day 0 (Pre-intervention) and Day 14 (post-intervention) | Venous blood samples will be taken and plasma glucose will be measured using a hexokinase method. |
| Secondary | Change from baseline plasma insulin at 14 days | Day 0 (Pre-intervention) and Day 14 (post-intervention) | Venous blood samples will be taken and plasma insulin will be measured using a high-sensitivity human insulin ELISA. |
| Secondary | Change from baseline plasma free fatty acids at 14 days | Day 0 (Pre-intervention) and Day 14 (post-intervention) | Venous blood samples will be taken and free fatty acids will be measured by colorimetric assay. |
| Secondary | Change from baseline interleukin-1(IL)-1beta at 14 days | Day 0 (Pre-intervention) and Day 14 (post-intervention) | Mature IL-1beta secretion will be quantified by ELISA run in duplicate |
| Secondary | Change from baseline caspase-1 activation at 14 days | Day 0 (Pre-intervention) and Day 14 (post-intervention) | Caspase-1 activation will be quantified by flow cytometry. The fluorescent inhibitor probe FAM-YVAD-FMK binds covalently to activated caspase-1 and emits at 530nm |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests5
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| 1-Back Task | Secondary outcome | ConductCognition |
| 2-Back Task | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Symbol Coding | Secondary outcome | ConductCognition |
| Task Switching Test | Secondary outcome | ConductCognition |
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03817749
GET https://conductscience.org/api/trials/v1/NCT03817749/registered